Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · Real-Time Price · USD

19.49

+1.08 (5.87%)

At close: Jul 27, 2026, 4:00 PM EDT

19.60

+0.11 (0.56%)

After-hours: Jul 27, 2026, 7:34 PM EDT

Amylyx Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	229.14	226.65	77.39	170.2	62.53	50.19
Short-Term Investments	50.63	90.33	99.11	201.16	284.42	45.93
Cash & Short-Term Investments	279.77	316.98	176.5	371.36	346.95	96.12
Cash Growth	37.09%	79.59%	-52.47%	7.04%	260.96%	646.43%
Accounts Receivable	-	0.09	0.45	40.05	15.31	-
Inventory	-	-	-	38.32	9.77	-
Other Current Assets	5.26	6.6	12.48	14.93	10.11	8.83
Total Current Assets	285.02	323.67	189.43	464.67	382.13	104.95
Net Property, Plant & Equipment	5.09	5.49	2.73	6.41	8.14	0.47
Other Long-Term Assets	3.49	3.48	1.47	46.38	1.19	0.19
Total Assets	293.6	332.65	193.63	517.45	391.45	105.61

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	3.53	3.52	2.94	22.06	6.26	4.37
Accrued Expenses	11.28	17.91	23.95	57.72	38.31	13.02
Current Portion of Leases	1.16	1.26	1.52	2.26	2.04	-
Total Current Liabilities	15.97	22.69	28.41	82.04	46.61	17.4
Long-Term Leases	4.48	4.7	0.46	1.98	4.24	-
Other Long-Term Liabilities	-	-	-	-	-	0.04
Total Long-Term Liabilities	4.48	4.7	0.46	1.98	4.24	0.04
Total Liabilities	20.44	27.39	28.87	84.02	50.85	17.43

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-in Capital	1,066	1,056	771.54	738.18	694.91	4.67
Accumulated Other Comprehensive Income	0.24	0.4	-0.09	0.2	-0.09	0.01
Retained Earnings	-792.71	-751.43	-606.69	-304.95	-354.22	-155.85
Total Common Shareholders' Equity	273.16	305.26	164.77	433.43	340.61	-151.17
Minority Interest	-	-	-	-	-	239.35
Shareholders' Equity	273.16	305.26	164.77	433.43	340.61	88.18
Total Liabilities & Equity	293.6	332.65	193.63	517.45	391.45	105.61

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	5.63	5.96	1.98	4.24	6.28	0
Net Cash (Debt)	274.14	311.02	174.52	367.13	340.67	96.12
Net Cash Growth	35.25%	78.22%	-52.46%	7.77%	254.43%	662.00%
Net Cash Per Share	2.72	3.29	2.56	5.25	5.82	14.59
Book Value	273.16	305.26	164.77	433.43	340.61	-151.17
Book Value Per Share	2.71	3.23	2.42	6.19	5.82	-22.95
Tangible Book Value	273.16	305.26	164.77	433.43	340.61	-151.17
Tangible Book Value Per Share	2.71	3.23	2.42	6.19	5.82	-22.95

SEC Filings: 10-K · 10-Q